¿¬¼ö°­ÁÂ
Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷ : 2023-04-07

Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷ : 2023-04-07
±³À°ÀÏÀÚ : 2023-04-07
±³À°Àå¼Ò : ¾Ú¹ö¼­´õ ¼­¿ï Ç®¸¸È£ÅÚ¿¡¼­

±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 2ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í Àü°øÀÇ, °£È£»ç, ±âŸ 50000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 08:20~08:40 Real-world experience of emicizumab prophylaxis in young children with hemophilia in China: retrospective data from China Wanru Yao(Beijing Children)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 08:40~09:00 TSUBASA: A prospective study evaluating the association between physical activity and bleeding events in patients with hemophilia A without FVIII inhibitors during emicizumab prophylaxis Keiji Nogami(Nara Medical University, Japan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 09:00~09:20 Gene therapy for hemophilia in China Feng Xue(Institute of Haematology and Blood Diseases Hospital, China)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 09:20~09:40 Hemophilia A murine models with transduced human factor IX and X for applications of factor VIII mimicking bi-specific antibodies Sheng Chieh Chou(National Taiwan University Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:05~10:25 Prothrombotic effect of emicizumab in an in vitro perfusion flow-chamber experiment using whole blood patients with von Willebrand disease Kenichi Ogiwara(Nara Medical University, Japan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:25~10:45 Managements of hemoperitoneum associated with ovulation in type 2 von Willebrand Disease: a single-institute experience in Taiwan Hsuan-Yu Lin(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 10:45~11:05 Chinese guidelines on the diagnosis and management of von Willebrand disease Ziqiang YuJie Yin(The First Affiliated Hospital of Soochow University, China)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 11:05~11:25 Genetic confirmation of Glanzmann thrombasthenia and other inherited platelet function disorders in Korea Ye Jee Shim(Keimyung University Dongsan Hospital, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 11:35~12:10 Status of hemophilia A and B gene therapies in 2023 Glenn Pierce(World Federation of Hemophilia, Canada)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 12:10~12:50 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MG1113 in Healthy Subjects and Hemophilia Patients Jung Woo Han(Yonsei University Health System, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 13:00~13:40 Non-inversion variant in sporadic hemophilia A originate mainly in female: a result of variant-origin and timing study Ming-Ching Shen(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 13:50~14:10 Therapeutic Outcomes of EHL Compared with SHL Clotting Factors in Patients with Severe Hemophilia in Taiwan Shyh-Shin Chiou(Kaohsiung Medical University Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:10~14:30 Joint monitoring using musculoskeletal ultrasound in Japan Azusa Nagao(Ogikubo Hospital, Japan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:30~14:50 Novel classification system of hemophilic pseudotumor for surgical treatment Xisheng Weng(Peking Union Medical College Hospital, China)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 14:50~15:10 Perioperative replacement of factor concentrates for orthopedic surgery in hemophilia A patients with hemophilic arthropathy Jae Joon Han(Kyung Hee University, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:35~15:45 A Phase 3 Study to Evaluate Efficacy and Safety of Fitusiran in People with Hemophilia A or B who Switched Factor or Bypassing Agent Prophylaxis Chur-Woo You(Daejeon Eulji Medical Center, Korea)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:45~15:55 Patients¡¯ and parents¡¯ satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study Ji Yoon Kim(Kyungpook National University School of Medicine)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 15:55~16:05 Analysis of Antithrombin Levels and Thrombin Generation a Phase 3 Study of Fitusiran in People with Hemophilia A or B Without inhibitors Alok Srivastava(Christian Medical College, India)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 16:05~16:15 The Comparisons of Deep Learning Algorithms to Grade Hemophilic Arthropathy on X ray films Shao Li Han(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04-07 ±×·£µåº¼·ë 16:15~16:25 Plasma long non-coding RNAs lncDC and THRIL as diagnostic markers of adult primary ITP Xin Li -> Nan Jiang(Qilu Hospital, China)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,317 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇѳ»ºÐºñÇÐȸ SICEM 2024(1ÀÏÂ÷) : 2024-04-11

±³À°ÀÏÀÚ : 2024-04-11 ±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼­¿ï ±³À°ÁÖÁ¦ : SICEM 2024(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ ´ã´çÀÚ : ¹Ú¼öºó ¿¬¶ôó : 02-2038-0

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,097 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,182 , ´ñ±Û¼ö : 0

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,937 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-17

±³À°ÀÏÀÚ : 2024-04-17 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã´çÀÚ : °­ÈÆ ¿¬¶ôó

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,081 , ´ñ±Û¼ö : 0